Editorial


Is there a safe time to stop clopidogrel in patients on dual antiplatelet therapy after a percutaneous coronary intervention and placement of drug-eluting stents?

Nureddin Almaddah, Rami N. Khouzam

Abstract

No clear evidence determines the most effective duration for dual antiplatelet therapy (DAPT) after drug-eluting stents (DES). Although DES reduces the rate of restenosis compared with bare-metal stents (BMS), it is of concern that they may be associated with a risk of stent thrombosis beyond 1 year post treatment. Many randomized clinical trials demonstrated the effectiveness of DAPT in preventing stent thrombosis; a serious complication of PCI. Additionally, it is believed that DAPT prevents adverse occurrences consequent to plaque rupture at a location other than the stented one. Such are the results of a study that compared medical treatment of acute coronary syndrome with Aspirin versus DAPT with clear reduction in the rate of myocardial infarction (MI) in patients who received DAPT (1).

Download Citation